Non-Accredited Satellite Symposia

A Potential New Path to Pain Relief:  Multimodal Analgesia for Enhanced Recovery with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)

Sunday, October 22 | 6:30 - 8 a.m.
The Westin Boston Waterfront, Harbor Ballroom 3, Conference Level

Presented by Cara Therapeutics, ASA Annual Meeting Supporter

Joseph Stauffer, D.O., M.B.A.

This symposium will describe how traditional mu opioid agonists play an important role in postoperative analgesia.  However, their use is associated with adverse effects such as respiratory depression, nausea and vomiting, which can delay postoperative recovery and increase healthcare costs.  In addition, mu opioid analgesics are responsible for morbidity and mortality due to the public health epidemics of abuse and overdose.  A novel peripherally acting kappa opioid receptor agonist (KORA), CR845, is currently in Phase 3 trials for postoperative pain (IV CR845) and Phase 2 trials for chronic pain (oral CR845).  Because of it's unique pharmacologic properties, CR845 has been shown to produce analgesia with little-to-no traditional mu opioid side effects and low abuse potential.  During this satellite symposium, the faculty will discuss analgesic drugs and techniques currently used in enhanced recovery after surgery (ERAS) protocols - an evolving paradigm for multimodal perioperative care, review the clinical data for CR845, and consider CR845's potential place in postoperative analgesia.  Register now


Helpful Information




The countdown to Boston has begun.
Be there.

ASA Membership Matters

ASA members receive deep discounts on registration. Join today before you register!

Learn more about submission opportunities

Submission Info